IL240730A0 - Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer - Google Patents
Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancerInfo
- Publication number
- IL240730A0 IL240730A0 IL240730A IL24073015A IL240730A0 IL 240730 A0 IL240730 A0 IL 240730A0 IL 240730 A IL240730 A IL 240730A IL 24073015 A IL24073015 A IL 24073015A IL 240730 A0 IL240730 A0 IL 240730A0
- Authority
- IL
- Israel
- Prior art keywords
- egfr
- inhibitor
- treatment
- combination
- lung cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786130P | 2013-03-14 | 2013-03-14 | |
PCT/IB2014/059401 WO2014140989A2 (en) | 2013-03-14 | 2014-03-03 | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL240730A0 true IL240730A0 (en) | 2015-10-29 |
Family
ID=50288209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL240730A IL240730A0 (en) | 2013-03-14 | 2015-08-20 | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2968336A2 (en) |
JP (1) | JP2014177456A (en) |
KR (1) | KR20150119210A (en) |
CN (1) | CN105073116A (en) |
AR (1) | AR095197A1 (en) |
AU (1) | AU2014229468A1 (en) |
BR (1) | BR112015023020A2 (en) |
CA (1) | CA2904797A1 (en) |
IL (1) | IL240730A0 (en) |
MX (1) | MX2015012106A (en) |
RU (1) | RU2015137596A (en) |
SG (1) | SG11201506531WA (en) |
TW (1) | TW201446248A (en) |
WO (1) | WO2014140989A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103814030A (en) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | Pyrrolopyrimidine and purine derivatives |
BR112016005881A2 (en) | 2013-09-18 | 2017-09-12 | Beijing Hanmi Pharmaceutical Co Ltd | compound, pharmaceutical composition and use of compound |
UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
TW201622744A (en) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | Combination therapy for cancer |
EP3201190A4 (en) * | 2014-10-01 | 2018-03-14 | Sun Pharmaceutical Industries Ltd | Crystalline form of afatinib dimaleate |
CN114224894A (en) * | 2014-12-03 | 2022-03-25 | 奥克兰联合服务有限公司 | Kinase inhibitor prodrugs for the treatment of cancer |
AU2016304852B2 (en) * | 2015-08-11 | 2020-12-10 | Principia Biopharma, Inc. | Processes for preparing an FGFR inhibitor |
US10583142B2 (en) | 2016-03-25 | 2020-03-10 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods of treatment |
WO2017164887A1 (en) * | 2016-03-25 | 2017-09-28 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods for treatment |
WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
EP3453392A4 (en) * | 2016-05-17 | 2020-03-04 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired egfr-tki resistance |
WO2017198602A1 (en) * | 2016-05-18 | 2017-11-23 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
TWI808958B (en) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
CN111433208B (en) | 2017-12-05 | 2023-06-30 | 奥斯考泰克公司 | Pyrrolo (pyrazolo) pyrimidine derivatives as LRRK2 inhibitors |
US20240059698A1 (en) * | 2022-07-29 | 2024-02-22 | Accutar Biotechnology Inc. | Heteroaryl compounds as egfr inhibitors and their uses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102146059A (en) * | 2010-02-08 | 2011-08-10 | 上海艾力斯医药科技有限公司 | Quinazoline derivatives and preparation method and application thereof |
CN103814030A (en) * | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | Pyrrolopyrimidine and purine derivatives |
-
2014
- 2014-03-03 BR BR112015023020A patent/BR112015023020A2/en not_active IP Right Cessation
- 2014-03-03 WO PCT/IB2014/059401 patent/WO2014140989A2/en active Application Filing
- 2014-03-03 CA CA2904797A patent/CA2904797A1/en not_active Abandoned
- 2014-03-03 CN CN201480014630.2A patent/CN105073116A/en active Pending
- 2014-03-03 EP EP14710651.2A patent/EP2968336A2/en not_active Withdrawn
- 2014-03-03 SG SG11201506531WA patent/SG11201506531WA/en unknown
- 2014-03-03 RU RU2015137596A patent/RU2015137596A/en not_active Application Discontinuation
- 2014-03-03 AU AU2014229468A patent/AU2014229468A1/en not_active Abandoned
- 2014-03-03 KR KR1020157024916A patent/KR20150119210A/en not_active Application Discontinuation
- 2014-03-03 MX MX2015012106A patent/MX2015012106A/en unknown
- 2014-03-10 AR ARP140100804A patent/AR095197A1/en unknown
- 2014-03-10 JP JP2014045949A patent/JP2014177456A/en active Pending
- 2014-03-11 TW TW103108449A patent/TW201446248A/en unknown
-
2015
- 2015-08-20 IL IL240730A patent/IL240730A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2968336A2 (en) | 2016-01-20 |
WO2014140989A3 (en) | 2014-12-04 |
SG11201506531WA (en) | 2015-09-29 |
JP2014177456A (en) | 2014-09-25 |
AU2014229468A1 (en) | 2015-09-03 |
AR095197A1 (en) | 2015-09-30 |
CA2904797A1 (en) | 2014-09-18 |
WO2014140989A2 (en) | 2014-09-18 |
BR112015023020A2 (en) | 2017-07-18 |
RU2015137596A (en) | 2017-04-17 |
KR20150119210A (en) | 2015-10-23 |
CN105073116A (en) | 2015-11-18 |
MX2015012106A (en) | 2016-01-12 |
TW201446248A (en) | 2014-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL240730A0 (en) | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer | |
IL268094B (en) | Derivatives of hetrerocyclic compounds for use in the treatment of lung cancer | |
IL273090B (en) | Methods and compositions for the treatment of cancer | |
HK1220110A1 (en) | Methods of treating lung cancer | |
LT3033086T (en) | Combination therapy for the treatment of cancer | |
EP3033079A4 (en) | Methods for the treatment of her2 amplified cancer | |
SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
IL242017B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
HK1213817A1 (en) | Methods of treating cancer | |
EP3008212A4 (en) | Methods of treatment of cancer | |
EP3733184C0 (en) | Pyrimidine compounds for use in the treatment of cancer | |
HK1219513A1 (en) | Methods of treating cancer | |
HUE038327T2 (en) | Treatment of lung cancer using the smad3 inhibitor sis3 | |
HK1223547A1 (en) | Methods for the treatment of cancer | |
HK1213475A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy ro5503781 | |
EP2953473A4 (en) | Cell therapy for the treatment of neurodegeneration | |
EP3016948B8 (en) | 2-acylaminothiazoles for the treatment of cancer | |
HK1214502A1 (en) | Combination of ro5503781 and capecitabine for cancer therapy ro5503781 | |
GB201317564D0 (en) | Therapeutic for the treatment of Lung Cancer |